Presynaptic I1-Imidazoline Receptors Reduce GABAergic Synaptic Transmission in Striatal Medium Spiny Neurons

作者: M. Tanabe

DOI: 10.1523/JNEUROSCI.4642-05.2006

关键词: NeurotransmissionEfaroxanIdazoxanInternal medicineChemistryMoxonidineReceptorCyclase activityPharmacologyImidazoline receptorEndocrinologyMedium spiny neuron

摘要: Imidazoline receptors are expressed widely in the CNS. In present study, whole-cell patch-clamp recordings were made from medium spiny neurons dorsal striatum slices rat brain, and roles of I1-imidazoline modulation synaptic transmission studied. Moxonidine, an receptor agonist, decreased GABAA receptor-mediated IPSCs a concentration-dependent manner. However, glutamate-mediated EPSCs hardly affected. The depression by moxonidine was antagonized either idazoxan or efaroxan, which both imidazoline antagonists containing moiety. contrast, yohimbine [SKF86466][1] (6-chloro-2,3,4,5-tetrahydro-3-methyl-1 H -3-benzazepine), α2-adrenergic with no affinity for receptors, did not affect moxonidine-induced inhibition IPSCs. Moxonidine increased paired-pulse ratio reduced frequency miniature without affecting their amplitude, indicating that this agent inhibits via presynaptic mechanisms. Moreover, sulfhydryl alkylating N -ethylmaleimide (NEM) significantly Thus, activation decreases GABA-mediated striatum, NEM-sensitive proteins such as Gi/o-type G-proteins play essential role. adenylate cyclase activator forskolin partly opposed IPSC elicited subsequently applied moxonidine. Furthermore, protein kinase C (PKC) phorbol 12,13-dibutyrate attenuated PKC inhibitor chelerythrine potentiated These results suggest involves intracellular activity is influenced static striatum. [1]: /lookup/external-ref?link_type=GENPEPT&access_num=SKF86466&atom=%2Fjneuro%2F26%2F6%2F1795.atom

参考文章(50)
Lincoln Edwards, Daniel Fishman, Peleg Horowitz, Nicole Bourbon, Mark Kester, Paul Ernsberger, The I1-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK) Journal of Neurochemistry. ,vol. 79, pp. 931- 940 ,(2008) , 10.1046/J.1471-4159.2001.00632.X
M Lafontan, C Carpéné, A Remaury, A Hudson, D Nutt, A Cordi, P Collon, Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites. Journal of Pharmacology and Experimental Therapeutics. ,vol. 272, pp. 681- 688 ,(1995)
J E Piletz, H Zhu, D N Chikkala, Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. Journal of Pharmacology and Experimental Therapeutics. ,vol. 279, pp. 694- 702 ,(1996)
P Ernsberger, L M Graff, M O Christen, T H Damon, S G Schäfer, Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. Journal of Pharmacology and Experimental Therapeutics. ,vol. 264, pp. 172- 182 ,(1993)
Gavin P. Reynolds, Ruth M. Boulton, Sally J. Pearson, Alan L. Hudson, David J. Nutt, Imidazoline binding sites in Huntington's and Parkinson's disease putamen. European Journal of Pharmacology. ,vol. 301, ,(1996) , 10.1016/0014-2999(96)00196-3
Yurika Kino, Mitsuo Tanabe, Motoko Honda, Hideki Ono, Involvement of supraspinal imidazoline receptors and descending monoaminergic pathways in tizanidine-induced inhibition of rat spinal reflexes. Journal of Pharmacological Sciences. ,vol. 99, pp. 52- 60 ,(2005) , 10.1254/JPHS.FP0050520
D.A Ruggiero, S Regunathan, H Wang, T.A Milner, D.J Reis, Immunocytochemical localization of an imidazoline receptor protein in the central nervous system Brain Research. ,vol. 780, pp. 270- 293 ,(1998) , 10.1016/S0006-8993(97)01203-1